NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario Saturday, April 28, 2007 - 8:30 a.m. - 12:00 p.m. Room: CARLYLE

Chairs: Drs. Greg Cairncross and Warren Mason

8:30 a.m.	Welcome and Introductions	W. Mason
	TRANSLATIONAL STUDIES	
8:40 a.m.	Canadian Brain Tumor Tissue Bank	A. Guha
	COMPLETED STUDIES	
8:50 a.m.	IND.170 – A phase I/II study of GW572016 in GBM	B. Thiessen
	New Trials	
9:00 a.m.	IND.162 – A phase I / II study of RAD001c plus Temozolomide in GBM	W. Mason
9:15 a.m.	CE.5-RT vs Temozolomide for low-grade glioma	W. Mason D. Rheaume
9:45 a.m.	CE.6-RT vs RT plus Temozolomide for elderly GBM	N. Laperriere J. Perry
10:00 a.m.	CEC.1 - A phase III trial of radiotherapy with and without concurrent and adjuvant temozolomide chemotherapy for 1p/19q non-deleted anaplastic gliomas	W. Mason C. O'Callaghan
10:15	COFFEE BREAK	
	FUTURE NCIC PHASE II / III STUDIES	
10:30 a.m.	Proposed HUB/RTOGNCIC/EORTC trial for 1p/19q deleted anaplastic gliomas	G. Cairncross

IDEAS FOR NEW BRAIN TUMOUR TRIALS

10:45 a.m.	Proposed NCIC CTG trial for newly-diagnosed GBM based on MGMT methylation status	J. Easaw
11:00 a.m.	NCCTG N0574: St RT with and without WBRT for 1-3 cerebral metastases methylation status	C. Menard
11:15 a.m.	Chloroquine with radiotherapy and temozolomide for newly diagnosed GBM	P. Cano
11:45 a.m.	Report from the NCIC CTG IND meeting	W. Mason
12:00 p.m.	ADJOURN	